Clinical trials recruiting for ALK-positive Non-small Cell Lung Cancer
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Lorlatinib | 3 |
| AQUA07 | 1 |
| Loratinib | 1 |
| NXP900 | 1 |
| TRI-611 | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Massachusetts | 2 |
| Virginia | 2 |
| California | 1 |
| Colorado | 1 |
| Missouri | 1 |
| New York | 1 |
| North Carolina | 1 |
| Ohio | 1 |
| Pennsylvania | 1 |
| Tennessee | 1 |
| Texas | 1 |
| Utah | 1 |
Top cities
Self-screener
Recruiting trials
- A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
- AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer
- Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC
- Patient-centered, Optimal Integration of Survivorship and Palliative Care
- Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients
- Study of NXP900 With Lorlatinib in ALK+ Lung Cancer
Related conditions
Trials recruiting for ALK-positive Non-small Cell Lung Cancer often also study these conditions. Each links to its own recruiting-trial list.
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for ALK-positive Non-small Cell Lung Cancer trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.